Painkiller gabapentin may shield kidneys during obesity surgery

NCT ID NCT06254183

Completed Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving a single dose of gabapentin before laparoscopic sleeve gastrectomy (weight-loss surgery) helps protect kidney function in people with severe obesity. 90 patients with normal kidney function were enrolled. Researchers measured kidney markers like creatinine and two newer biomarkers (NGAL and DKK3) to see if gabapentin reduces the risk of acute kidney injury after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gabapentin (a pain medication)
What this could lead to: If it works, this could point toward a simple way to reduce kidney injury after weight-loss surgery.
What could go wrong: This is a small, single-center Phase 4 trial with only 90 participants. The results may not apply to all patients or surgeries, and gabapentin can cause side effects like dizziness and drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury morbid obesity Obesity obesity disorder Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY BARIATRIC SURGERY CANDIDATE GABAPENTIN OBESITY (BMI > 35)

Contacts and locations

Locations

Tanta University

Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.